14 Nov, EOD - Indian

SENSEX 77580.31 (-0.14)

Nifty 50 23532.7 (-0.11)

Nifty Bank 50179.55 (0.18)

Nifty IT 42390.85 (0.05)

Nifty Midcap 100 54043.1 (0.45)

Nifty Next 50 67408.65 (0.46)

Nifty Pharma 21752 (-0.26)

Nifty Smallcap 100 17601.05 (0.81)

14 Nov, EOD - Global

NIKKEI 225 38642.91 (0.28)

HANG SENG 19426.34 (-0.05)

S&P 5912 (-1.31)

Login/Signup
LOGIN HERE
Cancel

Zim Laboratories Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 541400 | NSE Symbol : ZIMLAB | ISIN : INE518E01015 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
04-Nov-2024 09-Nov-2024 Quarterly Results Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2024 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Saturday 09th November 2024 to inter alia consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September 2024. In connection with the above as per SEBI (Prohibition of Insider Trading) Regulation 2015 and Companys Code of Conduct to Regulate Monitor and Report Trading by Insiders the trading window for dealing with securities of the Company is closed from Tuesday the 01st October 2024 to Monday the 11th November 2024 (both days inclusive). In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved : 1. Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended 30th September, 2024. Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed herewith. 2. Changes in the Senior Management of the Company : a. Categorization of Dr. Chandrashekhar Mainde, Technical Director as the Senior Management Personnel of the Company. b. Categorization of Dr. Uttam Kedar, Assistant Vice President - R&D as the Senior Management Personnel of the Company. The Board Meeting commenced at 03:00 p.m. and concluded at 06:15 p.m. (As Per BSE Announcement Dated on: 09/11/2024)
27-Jul-2024 03-Aug-2024 Quarterly Results Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2024 inter alia to consider and approve consideration and approval of unaudited financial results (standalone and consolidated) for the quarter ended 30.06.2024. In continuation to the above as per SEBI (PIT) Regulations 2015 and Companys Code of Conduct the trading window for dealing with the securities of the Company is closed from 01.07.2024 to 05.08.2024 (both days inclusive). In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved : 1. Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended 30th June, 2024. 2. Appointment of Protiviti India Member Private Limited as Internal Auditors of the Company for the F.Y. 2024-25. 3. Investment of upto Euro 1,53,000 in the equity shares of SIA ZIM Laboratories Limited, wholly owned subsidiary of the Company. 4. Incorporation of a Subsidiary of ZIM Laboratories FZE, Sharjah (wholly owned subsidiary of the Company). Post investment, the newly incorporated company would be a step-down subsidiary of the Company. Kindly take the intimation on record. Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board in its meeting held on 03rd August 2024 have approved the following: 1. Investment of up to Euro 1,53,000 in equity shares of SIA ZIM Laboratories Limited, WOS 2. Incorporation of subsidiary of ZIM Laboratories FZE (WOS). Post investment the newly incorporated subsidiary will be the step-down subsidiary of the Company (As Per BSE Announcement dated on 03.08.2024)
06-May-2024 13-May-2024 Quarterly Results Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2024 inter alia to consider and approve i) the Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended 31st March 2024. ii) the Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31st March 2024 (prepared pursuant to Regulation 33 of SEBI (LODR) Regulations 2015). In connection with the above as per SEBI (Prohibition of Insider Trading) Regulation 2015 and Companys Code of Conduct to Regulate Monitor and Report of Trading by Insiders the trading window for dealing with securities of the Company is closed from Monday 01st April 2024 to Wednesday 15th May 2024 (both days inclusive). In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today has inter-alia considered and approved: 1) the Financial Results and Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended 31.03.2024. Walker Chandiok & Co LLP, Chartered Accountants, the Statutory Auditors of the Company have issued auditor''s report with an unmodified opinion on the financial results for the year ended 31.03.2024 which is enclosed herewith. 2)Investment of upto Rs. 40 Lakhs in the equity shares of SIA ZIM Laboratories Limited, wholly owned subsidiary of the Company. 3)Investment of upto Rs. 02.00 crores in equity shares of ZIMTAS Pty Ltd., subsidiary of the Company. The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015, read with SEBI Circular dated 13.07.2023 are also enclosed as Annexure I & Annexure II. Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Acquisition The Board of Directors in their meeting held today has inter-alia considered and approved the financial results and audited financial statements (Standalone and Consolidated) of the Company for the year ended 31st March, 2024. (As Per BSE Announcement Dated on 13/05/2024)
22-Jan-2024 29-Jan-2024 Quarterly Results Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2024 inter alia to consider and approve the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31st December 2023. This is to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and nine months ended 31st December, 2023. Copy of unaudited Financial Results (Consolidated and Standalone) along with Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed. The Board Meeting commenced at 02:00 p.m. and concluded at 04:00 p.m. In compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that the Board of Directors of the Company at their meeting held on Monday 29th January, 2024 approved appointment of Ms. Yuti Nagarkar, Practicing Company Secretary as Secretarial Auditor of the Company to conduct Secretarial Audit for the F.Y. 2023-24 (As Per BSE Announcement Dated on 29/01/2024) Pursuant to Regulation 47 of the SEBI (LODR) Regulations, 2015, please find enclosed copy of newspaper publication regarding financial results for the quarter and nine months ended 31.12.2023. (As Per BSE Announcement Dated on 30/01/2024)
20-Dec-2023 23-Dec-2023 Employee Stock Option Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/12/2023 inter alia to consider and approve the ZIM Laboratories Employee Stock Option Scheme 2023 (ESOS 2023/ Scheme) pursuant to the provisions of Section 62(1)(b) other applicable provisions if any of the Companies Act 2013 read with rules framed thereunder and the relevant provisions of Regulation 6 of the Securities and Exchange Board of India (Share Based Employee Benefits & Sweat Equity) Regulations 2021 subject to the approval of shareholders of the Company by way of special resolution Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors in their meeting held today have inter-alia approved the 'ZIM Laboratories Employee Stock Option Scheme 2023' ('ESOS 2023'/ 'Scheme') pursuant to the provisions of Section 62(1)(b), other applicable provisions, if any, of the Companies Act, 2013 read with rules framed thereunder, and the relevant provisions of Regulation 6 of the Securities and Exchange Board of India (SBEB) Regulations, 2021, subject to the approval of shareholders of the Company by way of special resolution. The requisite disclosure pertaining to above as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, is enclosed herewith. The Board Meeting commenced at 01:00 p.m. and concluded at 03:20 p.m. (As Per BSE Announcement dated on 23.12.2023)
21-Oct-2023 01-Nov-2023 Quarterly Results Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2023 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Wednesday 01st November 2023 to inter alia consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September 2023. In connection with the above as per SEBI (Prohibition of Insider Trading) Regulation 2015 and Companys Code of Conduct to Regulate Monitor and Report Trading by Insiders the trading window for dealing with securities of the Company is closed from Sunday the 01st October 2023 to Friday the 03rd November 2023 (both days inclusive). This is to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended 30th September, 2023. Copy of unaudited Financial Results (Consolidated and Standalone) along with Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed. The Board Meeting commenced at 06:00 p.m. and concluded at 07:30 p.m. This is to inform you that the Board of Directors in their meeting held today have inter alia considered and approved unaudited Financial Results (Consolidate and Standalone) for quarter and half year ended 30.09.2023. The copy of unaudited financial results along with Limited Review Report is enclosed. (As per BSE Announcement Dated on 01/11/2023)
05-Aug-2023 14-Aug-2023 Quarterly Results Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 inter alia to consider and approve The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2023. This is to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended 30th June, 2023. Copy of the unaudited Financial Results (Consolidated and Standalone) along with Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed. This is to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended 30th June, 2023. (As Per BSE Announcement Dated on 14.08.2023)
28-Jun-2023 27-Jun-2023 Acquisitions Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors in their meeting held on 27th June, 2023, have considered and approved the following: a. Investment of AUD 9,900 (Australian Dollars) in an Australian Company namely ZIMTAS Pty. Ltd. b. Incorporation of a subsidiary in UAE by one of the Wholly owned Subsidiaries of the Company.
16-Jun-2023 16-Jun-2023 AGM Pursuant to Regulations 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors in their meeting held on 16th June, 2023, have decided that the Register of Members and the Share Transfer Book of the Company will remain closed from Tuesday, 04th July, 2023 till Monday, 10th July, 2023 (both days inclusive) for the purpose of Annual General Meeting.
10-May-2023 19-May-2023 Accounts Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2023 inter alia to consider and approve a) consider and approve the Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended 31st March 2023. b) consider and approve the Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31st March 2023 (prepared pursuant to Regulation 33 of SEBI (LODR) Regulations 2015). In connection with the above as per SEBI (Prohibition of Insider Trading) Regulation 2015 and Companys Code of Conduct to Regulate Monitor and Report of Trading by Insiders the trading window for dealing with securities of the Company is closed from Saturday 01st April 2023 to Sunday the 21st May 2023 (both days inclusive). In terms of Regulation 30 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today has inter-alia considered and approved: 1) the Audited Financial Statements (Standalone and Consolidated) of the Company for the year ended 31st March, 2023. 2) the Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended 31st March, 2023 (prepared pursuant to SEBI (LODR) Regulations, 2015). Walker Chandiok & Co LLP, Chartered Accountants, the Statutory Auditors of the Company have issued auditor''s report with an unmodified opinion on the financial results for the year ended 31.03.2023. (As Per BSE Announcement Dated on 19.05.2023)
25-Jan-2023 03-Feb-2023 Quarterly Results Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Friday the 03rd February 2023 to inter alia consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31st December 2022. In connection with the above as per SEBI (Prohibition of Insider Trading) Regulations 2015 and Companys Code of Conduct to regulate monitor and report trading by Insiders the trading window for dealing with securities of the Company is closed from Sunday the 01st January 2023 to Sunday the 05th February 2023 (both days inclusive). This is to inform you that the Board of Directors at its meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and nine months ended 31st December, 2022. Copy of Unaudited Financial Results (Consolidated and Standalone) along with Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditor of the Company is enclosed. (As Per BSE Announcement Dated on 03/02/2023)
23-Dec-2022 23-Dec-2022 Bonus Issue Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and in continuation to our intimations dated 12th November, 2022, 09th, 12th and 13th December, 2022 we hereby inform that the Board of Directors of the Company in their meeting held on 23rd December, 2022 have allotted 3,24,83,876 equity shares of Rs. 10 each as fully-paid up bonus equity shares, in the ratio of two equity shares for every existing one equity share, to eligible Members whose names appear in the register of Members/list of beneficial owners as on 22nd December, 2022, being the record date fixed for this purpose. The bonus equity shares as allotted shall rank pari-passu in all respects with the existing fully paid-up equity shares of the Company.
05-Nov-2022 12-Nov-2022 Quarterly Results Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2022 inter alia to consider and approve Pursuant to Regulation 29 of the Listing Regulations we hereby inform that a Meeting of the Board of Directors of the Company will be held on Saturday 12th November 2022 to inter-alia consider: a. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September 2022 and b. Proposal for issuance of Bonus Shares subject to approval by the shareholders of the Company. In connection with the above as per SEBI (Prohibition of Insider Trading) Regulation 2015 and Companys Code of Conduct to Regulate Monitor and Report Trading by Insiders the trading window for dealing with securities of the Company is closed from Saturday the 01st October 2022 to Monday the 14th November 2022 (both days inclusive). This is to inform you that the Board of Directors at its meeting held today have inter-alia considered and approved the following: a) Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September, 2022. b) Increase in Authorized Share Capital of the Company from Rs. 25,00,00,000/- divided into 2,50,00,000 Equity shares of 10/- each to Rs. 75,00,00,000/- divided into 7,50,00,000 equity shares of Rs. 10/- each and consequent amendment to Clause V of the Memorandum of Association of the Company, subject to the approval of the Shareholders in the General Meeting; and c) Issuance of Bonus Shares in the proportion of 2 (TWO) Equity Shares of Rs 10/- each for every 1 (ONE) existing Equity Share of Rs 10/- each held by the Shareholders of the Company as on the record date., subject to the approval of the Shareholders in the General Meeting. d) Convening Extraordinary General Meeting of the Company to be scheduled on Monday, 12th December, 2022 through video conferencing / other audio visual means for consideration and approval of items mentioned in (b) & (c) above by the shareholders of the Company (As Per BSE Bulletin Dated on 15.11.2022)
19-Jul-2022 26-Jul-2022 Quarterly Results Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2022 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors is scheduled to be held on Tuesday the 26th July 2022 to inter alia consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June 2022. In connection with the above as per SEBI (Prohibition of Insider Trading) Regulation 2015 and Companys Code of Conduct to Regulate Monitor and Report Trading by Insiders the trading window for dealing with securities of the Company is closed from Friday the 01st July 2022 to Thursday the 28th July 2022 (both days inclusive). This is to inform you that the Board of Directors at its meeting held today have inter-alia considered and approved Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended 30.06.2022. Copy of unaudited Financial Results (Consolidated and Standalone) along with Limited Review Report issued by Walker Chandiok & Co LLP, Statutory Auditors of the Company is enclosed. The Board Meeting commenced at 03:00 p.m. and concluded at 06:00 p.m. (As Per BSE Announcement dated on 26.07.2022)
06-Jun-2022 06-Jun-2022 EGM Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors on 06th June, 2022 have approved the issuance of Notice convening an Extra-ordinary General Meeting ('EGM') of the members of the Company to be held on Wednesday, 29th June, 2022 at 12:30 p.m. through Video Conferencing / Other Audio Visual Means, to seek approval of the members of the Company in respect of the proposed appointments/reappointments of the Directors.
1 2